Printed From:

QUESTIONS ABOUT NOVEL CORONAVIRUS?
CLICK HERE.

Real-world experience in UK centres

  • Manchester (Salford): A retrospective review at 3 and 6 months of records from 164 adult patients (≥18 years) with moderate-to-severe atopic dermatitis (AD) treated with DUPIXENT2
  • Specialist eczema clinic: A prospective 52-week observational cohort of 100 adult patients (≥18 years) with moderate-to-severe AD treated with DUPIXENT3

AD, atopic dermatitis; UK, United Kingdom.

References

  1. DUPIXENT Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/8553/smpc. Date accessed: July 2021.
  2. Kreeshan FC, et al. Dermatol Ther (Heidelb). 2021;11(1):149–160.
  3. Sears AV, et al. Br J Dermatol. 2021;184(4):755–757.